Originally developed to potentiate glucose-induced insulin release and for the treatment of diabetes mellitus, glucagon-like peptide-1 receptor (GLP-1R) agonists have been reported to have therapeutic efficacy in multiple animal models of neurodegenerative diseases27–31, alleviating the progression of neuropathology. The gene discussed is GLP1R; the disease is diabetes mellitus.